ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

In 15% to 30% of patients with acute myeloid leukemia (AML), aberrant proliferation is a consequence of a juxtamembrane mutation in the FLT3 gene (FMS-like tyrosine kinase 3–internal tandem duplication [FLT3-ITD]), causing constitutive kinase activity. ABT-869 (a multitargeted receptor tyrosine kina...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shankar, Deepa B., Li, Junling, Tapang, Paul, Owen McCall, J., Pease, Lori J., Dai, Yujia, Wei, Ru-Qi, Albert, Daniel H., Bouska, Jennifer J., Osterling, Donald J., Guo, Jun, Marcotte, Patrick A., Johnson, Eric F., Soni, Niru, Hartandi, Kresna, Michaelides, Michael R., Davidsen, Steven K., Priceman, Saul J., Chang, Jenny C., Rhodes, Katrin, Shah, Neil, Moore, Theodore B., Sakamoto, Kathleen M., Glaser, Keith B.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2007
Matèries:
Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852258/
https://ncbi.nlm.nih.gov/pubmed/17209055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-029579
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars